TICAM1

Across TCGA pan-cancer cohorts, TICAM1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TICAM1 data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TICAM1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TICAM1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

HNSC, UCEC, and PDAC are the cancer types where TICAM1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	0.833	0.474	.002	24	view →
UCEC	OS	Tertile	II,III,IV	1.000	0.420	.045	6	view →
PDAC	OS	Median	III,IV	0.890	0.265	.017	6	view →
LSCC	DFS	Median	II,III,IV	0.999	0.849	.013	5	view →
GBM	OS	Quartile	All	0.635	0.337	.034	4	view →
CCRCC	OS	Tertile	IV	1.000	0.189	.036	3	view →
LUAD	DFS	Quartile	All	0.453	0.817	.011	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TICAM1–HNSC (DFS)

Open the HNSC breakdown →